Form 4: Amneal Pharmaceuticals Executive Vice President Andrew Boyer Reports Stock Transactions
SEC Form 4
Executive Vice President Andrew Boyer reports acquisition and disposal of Amneal Pharmaceuticals Class A Common Stock and Restricted Stock Units.
Summary
- Andrew Boyer, Executive Vice President of Amneal Pharmaceuticals, reported transactions involving Class A Common Stock and Restricted Stock Units.
- On March 1, 2024, Boyer acquired 31,371 shares of Class A Common Stock and disposed of 16,219 shares at a price of $5.47.
- On March 3, 2024, Boyer acquired 39,251 shares, then 49,694 shares of Class A Common Stock and disposed of 19,665 shares, then 24,897 shares at a price of $5.47.
- On March 4, 2024, Boyer was granted 152,778 Restricted Stock Units and 305,556 Performance-Based Restricted Stock Units.
- Following these transactions, Boyer directly owns 319,381 shares of Class A Common Stock and 152,778 Restricted Stock Units and 305,556 Performance-Based Restricted Stock Units.
Sentiment
Score: 6
Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information. The sentiment is neutral to slightly positive due to the vesting of stock units.
Positives
- The granting of restricted stock units and performance-based restricted stock units to an executive could be seen as an incentive to improve company performance.
- Boyer's continued direct ownership of 319,381 shares of Class A Common Stock demonstrates a continued investment in the company.
Negatives
- The disposal of shares to cover tax obligations, while common, reduces the executive's holdings.
Risks
- The vesting of performance-based restricted stock units is contingent on achieving certain stock price targets, which may not be met.
- Fluctuations in the stock price could impact the value of the executive's holdings.
Future Outlook
The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in the executive's holdings.
- Employees may be indirectly impacted by the incentive structure created by the stock-based compensation.
Key Dates
| Date | Description |
|---|---|
| 03/01/2021 | Reporting person was granted 125,483 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. |
| 03/03/2022 | Reporting person was granted 157,005 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. |
| 03/03/2023 | Reporting person was granted 198,777 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. |
| 03/01/2024 | Transactions involving Class A Common Stock and Restricted Stock Units occurred. |
| 03/03/2024 | Transactions involving Class A Common Stock and Restricted Stock Units occurred. |
| 03/04/2024 | Grant of 152,778 Restricted Stock Units and 305,556 Performance-Based Restricted Stock Units. |
| 03/04/2025 | Restricted stock units vest in four equal annual installments beginning on this date. |
| 02/28/2027 | Performance-based restricted stock units vest on this date, the last day of the performance period. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.